{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:27:29Z","timestamp":1787509649833,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Autologous hematopoietic cell transplantation (HCT) has been introduced for patients with severe systemic sclerosis (SSc). We aimed to assess the safety and long-term efficacy of HCT modality for severe SSc, refractory to conventional therapy, in 17 patients who were referred to our \u2013 The Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT)-accredited Unit from 2005 to 2024. Peripheral blood stem cells were collected using cyclophosphamide and GCSF. An immunoablative conditioning regimen of cyclophosphamide and anti-thymocyte globulin was administered. Disease assessments were done before and after mobilization treatment and post-transplant, focusing on skin sclerosis, pulmonary function, cardiac involvement, gastrointestinal manifestations, the necessity for additional immunosuppressive therapy, and overall patient well-being. Before transplantation, 13\/17 (76%) of the patients had diffuse skin involvement with a mean mRSS of 31 (2\u201349), 2\/17 (12%) had pulmonary hypertension, and 14\/17 (82%) had gastrointestinal manifestations. The median follow-up period was 9.1 (0. 5\u201314. 3) years. Improvement of skin sclerosis was observed, with a decrease in mRSS before transplantation from 31 (2\u201349) to 7 (2\u201322) post-HCT. Lung function remained stable in 8\/15 (53%) patients, improved in 5\/15 (33%), and deteriorated in 2\/15 (13%). Gastrointestinal manifestations were improved in 12\/14 (86%) patients, while all patients (16\/16, 100%) reported a great impact on their quality of life. Ten out of the 16 (63%) patients were free of immunosuppressive drugs after the HCT. Overall survival was 16\/17 (94.2%). Concerning TRM, there was one (1\/17, 5.8%) death early post-transplant. In this specific cohort of selected patients with severe SSc refractory to immunosuppressive medications, autologous HCT led to improvements in the outcomes assessed.<\/jats:p>","DOI":"10.3389\/fmed.2025.1527779","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T05:25:29Z","timestamp":1752470729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Mallouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Batsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Bousiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spyridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Karavalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkistis kyra","family":"Panteliadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Dolgyras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Varelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlasios I.","family":"Alevizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis G.","family":"Asteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Vlachoyiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damianos","family":"Sotiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study","volume":"79","author":"van Bijnen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European scleroderma trial and research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13075-021-02672-y","article-title":"Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality","volume":"23","author":"De Almeida Chaves","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cells11233912","article-title":"Hematopoietic cell transplantation for systemic sclerosis-a review","volume":"11","author":"Levin","year":"2022","journal-title":"Cells"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.3390\/ijerph192215088","article-title":"Secular trends in systemic sclerosis mortality in the United States from 1981 to 2020","volume":"19","author":"Li","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acr.24411","article-title":"Trends in systemic sclerosis mortality over forty-eight years, 1968-2015: a US population-based study","volume":"73","author":"Yen","year":"2021","journal-title":"Arthritis Care Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","article-title":"Predictors of morbidity and mortality in early systemic sclerosis: long-term follow-up data from a single-Centre inception cohort","volume":"17","author":"Panopoulos","year":"2018","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00432-024-05815-1","article-title":"High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factors","volume":"150","author":"Pyka","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/biomedicines10020504","article-title":"Emerging evidence and treatment perspectives from randomized clinical trials in systemic sclerosis: focus on interstitial lung disease","volume":"10","author":"Aragona","year":"2022","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-40658-4_5","article-title":"Classification and disease subsets in clinical practice","volume-title":"Scleroderma","author":"Johnson","year":"2024"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.55563\/clinexprheumatol\/dhn3mb","article-title":"Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation","volume":"39","author":"Panopoulos","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s42358-024-00392-w","article-title":"Brazilian Society of Rheumatology Guidelines for the treatment of systemic sclerosis","volume":"64","author":"Kayser","year":"2023","journal-title":"Adv Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for Management of Systemic Sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","article-title":"Autologous stem cell transplantation with Thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations","volume":"53","author":"Henes","year":"2014","journal-title":"Rheumatology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/2397198320985766","article-title":"Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: three successful cases and review of the literature","volume":"6","author":"Shah","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/ard.55.10.779","article-title":"Autologous Haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease","volume":"55","author":"Tamm","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"ref27","volume-title":"Hematopoietic stem cell transplantation","author":"van Laar","year":"2024"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-Myeloablative Haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-024-03408-4","article-title":"Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents","volume":"26","author":"Del Papa","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","article-title":"CD34-selected versus Unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42358-021-00166-8","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience","volume":"61","author":"Henrique-Neto","year":"2021","journal-title":"Adv Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/cells11050843","article-title":"Autologous haematopoietic stem cell transplantation and systemic sclerosis: focus on interstitial lung disease","volume":"11","author":"Bagnato","year":"2022","journal-title":"Cells"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15993","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature","volume":"178","author":"Eyraud","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/S0140-6736(13)61240-4","article-title":"Autologous HSCT for systemic sclerosis","volume":"381","author":"Sakellari","year":"2013","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-019-1842-x","article-title":"Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2397198319891282","article-title":"Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches","volume":"6","author":"Hoffmann-Vold","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review","volume":"59","author":"Puyade","year":"2020","journal-title":"Rheumatology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/BOR.0000000000001050","article-title":"Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease","volume":"36","author":"Zielonka","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e000533","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Oliver Distler haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3899\/jrheum.111302","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: \u201cit is a matter of the heart\u201d","volume":"39","author":"Burt","year":"2012","journal-title":"J Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"817893","DOI":"10.3389\/fimmu.2021.817893","article-title":"Immunosuppressive therapy after autologous hematopoietic stem cell transplantation in systemic sclerosis patients-high efficacy of rituximab","volume":"12","author":"Gernert","year":"2021","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/rheumatology\/kead457","article-title":"Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy","volume":"63","author":"Keret","year":"2023","journal-title":"Rheumatology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","article-title":"A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol","volume":"11","author":"Spierings","year":"2021","journal-title":"BMJ Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1527779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T05:25:30Z","timestamp":1752470730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1527779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1527779"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1527779","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"article-number":"1527779"}}